Search

Your search keyword '"Diamant, Zuzana"' showing total 443 results
Start Over Author "Diamant, Zuzana" Publication Year Range Last 10 years
443 results on '"Diamant, Zuzana"'

5. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline

Author

Khatri, Sumita B, Iaccarino, Jonathan M, Barochia, Amisha, Soghier, Israa, Akuthota, Praveen, Brady, Anna, Covar, Ronina A, Debley, Jason S, Diamant, Zuzana, Fitzpatrick, Anne M, Kaminsky, David A, Kenyon, Nicholas J, Khurana, Sandhya, Lipworth, Brian J, McCarthy, Kevin, Peters, Michael, Que, Loretta G, Ross, Kristie R, Schneider-Futschik, Elena K, Sorkness, Christine A, and Hallstrand, Teal S

Subjects
Lung, Clinical Trials and Supportive Activities, Clinical Research, Asthma, 7.3 Management and decision making, Management of diseases and conditions, Respiratory, Adrenal Cortex Hormones, Anti-Asthmatic Agents, Humans, Nitric Oxide, Practice Guidelines as Topic, United States, nitric oxide, asthma, inhaled steroids, airway disease, type 2 inflammation, American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, Medical and Health Sciences, Respiratory System
Abstract

Background: The fractional exhaled nitric oxide (FENO) test is a point-of-care test that is used in the assessment of asthma. Objective: To provide evidence-based clinical guidance on whether FENO testing is indicated to optimize asthma treatment in patients with asthma in whom treatment is being considered. Methods: An international, multidisciplinary panel of experts was convened to form a consensus document regarding a single question relevant to the use of FENO. The question was selected from three potential questions based on the greatest perceived impact on clinical practice and the unmet need for evidence-based answers related to this question. The panel performed systematic reviews of published randomized controlled trials between 2004 and 2019 and followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework to develop recommendations. All panel members evaluated and approved the recommendations. Main Results: After considering the overall low quality of the evidence, the panel made a conditional recommendation for FENO-based care. In patients with asthma in whom treatment is being considered, we suggest that FENO is beneficial and should be used in addition to usual care. This judgment is based on a balance of effects that probably favors the intervention; the moderate costs and availability of resources, which probably favors the intervention; and the perceived acceptability and feasibility of the intervention in daily practice. Conclusions: Clinicians should consider this recommendation to measure FENO in patients with asthma in whom treatment is being considered based on current best available evidence.

Published
2021

8. EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients

Author

Diamant, Zuzana, Jesenak, Milos, Hanania, Nicola A., Heaney, Liam G., Djukanovic, Ratko, Ryan, Dermot, Quirce, Santiago, Backer, Vibeke, Gaga, Mina, Pavord, Ian, Antolín-Amérigo, Darío, Assaf, Sara, Bakakos, Petros, Bobcakova, Anna, Busse, William, Kappen, Jasper, Loukides, Stelios, van Maaren, Maurits, Panzner, Petr, Pite, Helena, Spanevello, Antonio, Stenberg, Henning, Striz, Ilja, Thio, Boony, Vasakova, Martina Koziar, Conti, Diego, Fokkens, Wytske, Lau, Susanne, Scadding, Glenis K., Van Staeyen, Elizabeth, Hellings, Peter W., and Bjermer, Leif

Published
2023
Full Text
View/download PDF

11. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology

Author

Seys, Sven F., Hellings, Peter W., Alobid, Isam, Backer, Vibeke, Bequignon, Emilie, von Buchwald, Christian, Cavaliere, Carlo, Coste, André, Deneyer, Lauren, Diamant, Zuzana, Eckl-Dorna, Julia, Fokkens, Wytske J., Gane, Simon, Gevaert, Philippe, Holbaek-Haase, Christiane, Holzmeister, Clemens, Hopkins, Claire, Hox, Valérie, Huart, Caroline, Jankowski, Roger, Jorissen, Mark, Kjeldsen, Anette, Knipps, Lisa, Lange, Bibi, van der Lans, Rik, Laulajainen-Hongisto, Anu, Larsen, Kenneth, Liu, David T., Lund, Valerie, Mariën, Gert, Masieri, Simonetta, Mortuaire, Geoffrey, Mullol, Joaquim, Reitsma, Sietze, Rombaux, Philippe, Schneider, Sven, Steinsvik, Andreas, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna K., Van Gerven, Laura, Van Zele, Thibaut, Virkkula, Paula, Wagenmann, Martin, and Bachert, Claus

Published
2023
Full Text
View/download PDF

12. Digital tools in allergy and respiratory care

Author

Verhoeven, Elisabeth, Rouadi, Philip, Jaoude, Eliane Abou, Abouzakouk, Mohamed, Ansotegui, Ignacio, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Azar, Cecilio, Bahna, Sami, Cuervo-Pardo, Lyda, Diamant, Zuzana, Douagui, Habib, Maximiliano Gómez, R., Díaz, Sandra González, Han, Joseph K., Idriss, Samar, Irani, Carla, Karam, Marilyn, Klimek, Ludger, Nsouli, Talal, Scadding, Glenis, Senior, Brent, Smith, Pete, Yáñez, Anahí, Zaitoun, Fares, and Hellings, Peter W.

Published
2022
Full Text
View/download PDF

15. Recommendations for asthma monitoring in children:A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

Author

Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., Zar, Heather J., Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., and Zar, Heather J.

Abstract

Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even “real-time,” monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design. (Figure presented.).

Published
2024

16. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.

Author

Hellings, Peter W., Alobid, Isam, Anselmo‐Lima, Wilma T., Bernal‐Sprekelsen, Manuel, Bjermer, Leif, Caulley, Lisa, Chaker, Adam, Constantinidis, Jannis, Conti, Diego M., De Corso, Eugenio, Desrosiers, Martin, Diamant, Zuzana, Gevaert, Philippe, Han, Joseph K., Heffler, Enrico, Hopkins, Claire, Landis, Basile N., Lourenco, Olga, Lund, Valerie, and Luong, Amber U.

Subjects
NASAL polyps, ENDOSCOPIC surgery, SINUSITIS, REOPERATION, PHYSICIANS, ASPIRIN
Abstract

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank

Author

Mathioudakis, Alexander G., Custovic, Adnan, Deschildre, Antoine, Ducharme, Francine M., Kalayci, Omer, Murray, Clare, Garcia, Antonio Nieto, Phipatanakul, Wanda, Price, David, Sheikh, Aziz, Agache, Ioana, Bacharier, Leonard, Bonini, Matteo, Castro-Rodriguez, Jose A., De Carlo, Giuseppe, Craig, Timothy, Diamant, Zuzana, Feleszko, Wojciech, Ierodiakonou, Despo, Gern, James E., Grigg, Jonathan, Hedlin, Gunilla, Hossny, Elham M., Jartti, Tuomas, Kaplan, Alan, Lemanske, Robert F., Le Souef, Peter, Makela, Mika J., Matricardi, Paolo M., Miligkos, Michael, Morais-Almeida, Mário, Pite, Helena, Pitrez, Paulo M.C., Pohunek, Petr, Roberts, Graham, Sanchez-Garcia, Sylvia, Tsiligianni, Ioanna, Turner, Steve, Winders, Tonya A., Wong, Gary, Xepapadaki, Paraskevi, Zar, Heather J., and Papadopoulos, Nikolaos G.

Published
2020
Full Text
View/download PDF

21. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

Author

Hellings, Peter W., primary, Alobid, Isam, additional, Anselmo‐Lima, Wilma T., additional, Bernal‐Sprekelsen, Manuel, additional, Bjermer, Leif, additional, Caulley, Lisa, additional, Chaker, Adam, additional, Constantinidis, Jannis, additional, Conti, Diego M., additional, De Corso, Eugenio, additional, Desrosiers, Martin, additional, Diamant, Zuzana, additional, Gevaert, Philippe, additional, Han, Joseph K., additional, Heffler, Enrico, additional, Hopkins, Claire, additional, Landis, Basile N., additional, Lourenco, Olga, additional, Lund, Valerie, additional, Luong, Amber U., additional, Mullol, Joaquim, additional, Peters, Anju, additional, Philpott, Carl, additional, Reitsma, Sietze, additional, Ryan, Dermot, additional, Scadding, Glenis, additional, Senior, Brent, additional, Tomazic, Peter Valentin, additional, Toskala, Elina, additional, Van Zele, Thibaut, additional, Viskens, An‐Sofie, additional, Wagenmann, Martin, additional, and Fokkens, W. J., additional

Published
2023
Full Text
View/download PDF

23. EUFOREA/EPOS2020 Statement on the Clinical Considerations for CRSwNP Care

Author

Fokkens, Wytske, primary, Hellings, Peter, additional, Alobid, Isam, additional, Anselmo-Lima, Wilma, additional, Bernal-Sprekelsen, Manuel, additional, Bjermer, Leif, additional, Caulley, Lisa, additional, Chaker, Adam, additional, Constantinidis, Jiannis, additional, Conti, Diego M., additional, E., De Corso, additional, Desrosiers, Martin, additional, Diamant, Zuzana, additional, Gevaert, Philippe, additional, J, Han Han., additional, Heffler, Enrico, additional, Hopkins, Clair, additional, Landis, Basile, additional, Lourenço, Olga, additional, Lund, Valerie, additional, Luong, Amber, additional, Mullol, Joaquim, additional, Peters, Anju, additional, Philpott, Carl, additional, Reitsma, Sietze, additional, Ryan, Dermot, additional, Scadding, Glenis, additional, Senior, Brent, additional, Tomazic, Peter, additional, Toskala, Elina, additional, Zele, Thibaut van, additional, Viskens, Sofie, additional, and Wagenmann, Martin, additional

Published
2023
Full Text
View/download PDF

25. Eosinophils—from cradle to grave

Author

Jesenak, Milos, primary, Diamant, Zuzana, additional, Simon, Dagmar, additional, Tufvesson, Ellen, additional, Seys, Sven F., additional, Mukherjee, Manali, additional, Lacy, Paige, additional, Vijverberg, Susanne, additional, Slisz, Tomas, additional, Sediva, Anna, additional, Simon, Hans‐Uwe, additional, Striz, Ilja, additional, Plevkova, Jana, additional, Schwarze, Jurgen, additional, Kosturiak, Radovan, additional, Alexis, Neil E., additional, Untersmayr, Eva, additional, Vasakova, Martina Koziar, additional, Knol, Edward, additional, and Koenderman, Leo, additional

Published
2023
Full Text
View/download PDF

26. Evaluating treatment response to mepolizumab in patients with severe CRSwNP*

Author

Hopkins, Claire, Han, Joseph K., Lund, Valerie J., Bachert, Claus, Fokkens, Wytske J., Diamant, Zuzana, Mullol, Joaquim, Sousa, Ana R., Smith, Steven G., Yang, Shibing, Mayer, Bhabita, Yancey, Steve W., Chan, Robert H., and Lee, Stella E.

Subjects
nasal polyps, biological products, mepolizumab, systemic corticosteroid use, disease-specific quality of life
Abstract

Background: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP). Methods: SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS). Results: Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across ≥ 3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories). Conclusions: Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.

Published
2023

33. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper

Author

Kappen, Jasper, primary, Diamant, Zuzana, additional, Agache, Ioana, additional, Bonini, Matteo, additional, Bousquet, Jean, additional, Canonica, G. Walter, additional, Durham, Stephen R., additional, Guibas, George V., additional, Hamelmann, Eckard, additional, Jutel, Marek, additional, Papadopoulos, Nikolaos G., additional, Roberts, Graham, additional, Shamji, Mohamed H., additional, Zieglmayer, Petra, additional, Gerth van Wijk, Roy, additional, and Pfaar, Oliver, additional

Published
2023
Full Text
View/download PDF

34. Functional imaging for assessing regional lung ventilation in preclinical and clinical research

Author

Karmali, Dipan, primary, Sowho, Mudiaga, additional, Bose, Sonali, additional, Pearce, Jackson, additional, Tejwani, Vickram, additional, Diamant, Zuzana, additional, Yarlagadda, Keerthi, additional, Ponce, Erick, additional, Eikelis, Nina, additional, Otvos, Tamas, additional, Khan, Akram, additional, Lester, Michael, additional, Fouras, Andreas, additional, Kirkness, Jason, additional, and Siddharthan, Trishul, additional

Published
2023
Full Text
View/download PDF

37. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up.

Author

Desrosiers, Martin, Diamant, Zuzana, Castelnuovo, Paolo, Hellings, Peter W., Han, Joseph K., Peters, Anju T., Silver, Jared, Smith, Steven G., Fuller, Abigail, Sousa, Ana R., Chan, Robert H., and Gevaert, Philippe

Subjects
*NASAL tumors, *NASAL polyps, *SINUSITIS, *SYNAPSES, *END of treatment, *VISUAL analog scale, *PHYSICIANS
Abstract

Background: In the 52‐week Phase III SYNAPSE study, mepolizumab given every 4 weeks (100 mg subcutaneously) reduced nasal polyp (NP) size, improved symptoms and quality of life (QoL), and reduced corticosteroid use and number of sinus surgeries in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), versus placebo. Because the durability of mepolizumab's efficacy after discontinuation is poorly understood in CRSwNP, the efficacy of mepolizumab after discontinuation was analyzed in severe CRSwNP, over a 24‐week follow‐up. Methods: Changes from SYNAPSE baseline to end of treatment (week 52) and end of follow‐up (week 76) were assessed for total endoscopic NP score, nasal obstruction and overall symptoms visual analog scale scores, and 22‐item Sino‐Nasal Outcome Test score. Time to first sinus surgery, time to first corticosteroid use, and geometric mean blood eosinophil counts (BECs) were also assessed. Results: Among 134 follow‐up patients, clinical improvements observed with mepolizumab versus placebo were partially evident 24 weeks after discontinuation despite BEC returning to baseline. The mean (95% confidence interval [CI]) change from baseline in NP score (week 52: −1.3 [1.8 to −0.9] vs. −0.3 [−0.6 to 0.1]; week 76: −1.2 [−1.6 to −0.7] vs. −0.1 [−0.5 to 0.3]) and the proportion of patients having sinus surgery (week 52: 4% vs. 25%; week 76: 9% vs. 31%) remained substantially improved with mepolizumab versus placebo. Mepolizumab‐associated improvements in overall symptoms, quality of life, and corticosteroid use versus placebo were partially sustained at week 76. Conclusion: Fifty‐two weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered by physicians when making treatment decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. A EUFOREA comment on a lost comorbidity of asthma

Author

Conti, Diego M, Hellings, Peter W, Diamant, Zuzana, Bjermer, Leif, Jesenak, Milos, Backer, Vibeke, Fokkens, Wytske, Lau, Susanne, Van Staeyen, Elizabeth, and Scadding, Glenis K

Subjects
Chronic rhinosinusitis without nasal polyps, Allergic rhinitis, Asthma, Chronic rhinosinusitis with nasal polyps, Comorbidities
Abstract

"Epidemiology of comorbidities and their association with asthma control" (Tomisa, G., Horváth, A., Sánta, B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol 17, 95 (2021). https://doi.org/10.1186/s13223-021-00598-3 ) is an interesting paper reflecting data collection from more than 12,000 asthmatic patients in Hungary regarding their condition and associated comorbidities. We found it valuable that the paper provides an overview of asthma comorbidities not usually considered in similar reports. Nevertheless, we believe that chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) should have been listed due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS, as well as in several peer-reviewed scientific papers, and to reflect the role of this comorbidity in poor control and a most severe presentation of asthma for the patient. Consequently, several targeted therapies (especially monoclonal antibodies) used for several years in severe forms of asthma are now indicated also for the effective treatment of nasal polyps. ispartof: ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY vol:19 issue:1 ispartof: location:England status: published

Published
2023

41. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma:An EAACI position paper

Author

Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, Pfaar, Oliver, Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, and Pfaar, Oliver

Abstract

Introduction: In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, the evidence for efficacy is based on controlled clinical trials following standardized endpoint measures. However, so far there is a lack of a consensus for asthma endpoints in AIT trials. The aim of a task force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) is evaluating several outcome measures for AIT in allergic asthma. Methods: The following domains of outcome measures in asthmatic patients have been evaluated for this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms and rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) allergen exposure chambers (AEC) and (viii) biomarkers. Results: Exacerbation rate can be used as a reliable objective primary outcome; however, there is limited evidence due to different definitions of exacerbation. The time after ICS withdrawal to first exacerbation is considered a primary outcome measure. Besides, the advantages and disadvantages and clinical implications of further domains of asthma endpoints in AIT trials are elaborated in this PP. Conclusion: This EAACI-PP aims to highlight important aspects of current asthma measures by critically evaluating their applicability for controlled trials of AIT.

Published
2023

42. EUFOREA pocket guide on the diagnosis and management of asthma:An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients

Author

Diamant, Zuzana, Jesenak, Milos, Hanania, Nicola A., Heaney, Liam G., Djukanovic, Ratko, Ryan, Dermot, Quirce, Santiago, Backer, Vibeke, Gaga, Mina, Pavord, Ian, Antolín-Amérigo, Darío, Assaf, Sara, Bakakos, Petros, Bobcakova, Anna, Busse, William, Kappen, Jasper, Loukides, Stelios, van Maaren, Maurits, Panzner, Petr, Pite, Helena, Spanevello, Antonio, Stenberg, Henning, Striz, Ilja, Thio, Boony, Vasakova, Martina Koziar, Conti, Diego, Fokkens, Wytske, Lau, Susanne, Scadding, Glenis K., Van Staeyen, Elizabeth, Hellings, Peter W., Bjermer, Leif, Diamant, Zuzana, Jesenak, Milos, Hanania, Nicola A., Heaney, Liam G., Djukanovic, Ratko, Ryan, Dermot, Quirce, Santiago, Backer, Vibeke, Gaga, Mina, Pavord, Ian, Antolín-Amérigo, Darío, Assaf, Sara, Bakakos, Petros, Bobcakova, Anna, Busse, William, Kappen, Jasper, Loukides, Stelios, van Maaren, Maurits, Panzner, Petr, Pite, Helena, Spanevello, Antonio, Stenberg, Henning, Striz, Ilja, Thio, Boony, Vasakova, Martina Koziar, Conti, Diego, Fokkens, Wytske, Lau, Susanne, Scadding, Glenis K., Van Staeyen, Elizabeth, Hellings, Peter W., and Bjermer, Leif

Published
2023

43. Allergen immunotherapy for allergic asthma:The future seems bright

Author

Diamant, Zuzana, van Maaren, Maurits, Muraro, Antonella, Jesenak, Milos, Striz, Ilja, Diamant, Zuzana, van Maaren, Maurits, Muraro, Antonella, Jesenak, Milos, and Striz, Ilja

Abstract

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

Published
2023

44. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR):Establishment of an International Outcome Registry Driven by mHealth Technology

Author

Seys, Sven F., Hellings, Peter W., Alobid, Isam, Backer, Vibeke, Bequignon, Emilie, von Buchwald, Christian, Cavaliere, Carlo, Coste, André, Deneyer, Lauren, Diamant, Zuzana, Eckl-Dorna, Julia, Fokkens, Wytske J., Gane, Simon, Gevaert, Philippe, Holbaek-Haase, Christiane, Holzmeister, Clemens, Hopkins, Claire, Hox, Valérie, Huart, Caroline, Jankowski, Roger, Jorissen, Mark, Kjeldsen, Anette, Knipps, Lisa, Lange, Bibi, van der Lans, Rik, Laulajainen-Hongisto, Anu, Larsen, Kenneth, Liu, David T., Lund, Valerie, Mariën, Gert, Masieri, Simonetta, Mortuaire, Geoffrey, Mullol, Joaquim, Reitsma, Sietze, Rombaux, Philippe, Schneider, Sven, Steinsvik, Andreas, Tomazic, Peter Valentin, Toppila-Salmi, Sanna K., Van Gerven, Laura, Van Zele, Thibaut, Virkkula, Paula, Wagenmann, Martin, Bachert, Claus, Seys, Sven F., Hellings, Peter W., Alobid, Isam, Backer, Vibeke, Bequignon, Emilie, von Buchwald, Christian, Cavaliere, Carlo, Coste, André, Deneyer, Lauren, Diamant, Zuzana, Eckl-Dorna, Julia, Fokkens, Wytske J., Gane, Simon, Gevaert, Philippe, Holbaek-Haase, Christiane, Holzmeister, Clemens, Hopkins, Claire, Hox, Valérie, Huart, Caroline, Jankowski, Roger, Jorissen, Mark, Kjeldsen, Anette, Knipps, Lisa, Lange, Bibi, van der Lans, Rik, Laulajainen-Hongisto, Anu, Larsen, Kenneth, Liu, David T., Lund, Valerie, Mariën, Gert, Masieri, Simonetta, Mortuaire, Geoffrey, Mullol, Joaquim, Reitsma, Sietze, Rombaux, Philippe, Schneider, Sven, Steinsvik, Andreas, Tomazic, Peter Valentin, Toppila-Salmi, Sanna K., Van Gerven, Laura, Van Zele, Thibaut, Virkkula, Paula, Wagenmann, Martin, and Bachert, Claus

Abstract

Background: Real-world evidence (RWE) is a valuable instrument to better understand the patient journey and effectiveness of therapies. RWE on the prevalence of uncontrolled chronic rhinosinusitis (CRS) and CRS natural course of disease across Europe is scarce. In addition, there is limited RWE that enables comparison of the effectiveness of marketed therapies including topical or systemic corticosteroids, sinus surgery, or biologics. Objective: To establish an international CHRonic rhINOSinusitis Outcome Registry (CHRINOSOR) based on real-world data collection enabled by mobile health technology. Methodology: A digital platform, Galenus Health, supporting patients and physicians in the management of chronic respiratory diseases, is used to collect data on patient profile, disease history, patient outcomes, and a set of relevant clinical outcomes. Adult patients with a diagnosis of CRS are eligible for inclusion. Results: A collaborative scientific network of 17 university ear-nose-throat (ENT) clinics from 10 European countries has been established with the aim to collect real-world data in a longitudinal and standardized manner. The Galenus Health digital platform is currently being implemented in these ENT clinics taking into account legal, privacy, and data security aspects. Up to 300 patients have already been included. Conclusions: CHRINOSOR is a collaborative effort that aims at improving our understanding of CRS, its comorbidities, and the effectiveness of its treatments. Ultimately, these insights will guide us as scientific community to develop future care pathways informed by RWE.

Published
2023

49. Additional file 1 of Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Author

Fokkens, Wytske, Trigg, Andrew, Lee, Stella E., Chan, Robert H., Diamant, Zuzana, Hopkins, Claire, Howarth, Peter, Lund, Valerie, Mayer, Bhabita, Sousa, Ana R., Yancey, Steve, and Tabberer, Maggie

Abstract

Additional file 1. Supplementary methods and results.

Published
2023
Full Text
View/download PDF

50. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

Author

Sokolowska, Milena, Rovati, G Enrico, Diamant, Zuzana, Untersmayr, Eva, Schwarze, Jürgen, Lukasik, Zuzanna, Sava, Florentina, Angelina, Alba, Palomares, Oscar, Akdis, Cezmi A, et al, University of Zurich, and Sokolowska, Milena

Subjects
2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results